Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States

Alexander C Schmidt, Leyi Lin, Luis J Martinez, Richard C Ruck, Kenneth H Eckels, Alix Collard, Rafael De La Barrera, Kristopher M Paolino, Jean-François Toussaint, Edith Lepine, Bruce L Innis, Richard G Jarman, Stephen J Thomas, Alexander C Schmidt, Leyi Lin, Luis J Martinez, Richard C Ruck, Kenneth H Eckels, Alix Collard, Rafael De La Barrera, Kristopher M Paolino, Jean-François Toussaint, Edith Lepine, Bruce L Innis, Richard G Jarman, Stephen J Thomas

Abstract

AbstractThe safety and immunogenicity of four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV), formulated at 1 or 4 μg with aluminum hydroxide (alum) or at 1 μg with an adjuvant system (AS01E or AS03B), were evaluated in a first-time-in-human, placebo-controlled, randomized, observer-blind, phase 1 trial in the continental United States. Two doses of vaccine or placebo were administered intramuscularly 4 weeks apart to 100 healthy adults 18-39 years of age, randomized 1:1:1:1:1 to receive one of four DPIV formulations or saline placebo. The response to a third dose was evaluated in a subset of nine participants remote from primary vaccination. Humoral immunogenicity was assessed using a 50% microneutralization assay. All DPIV formulations were well tolerated. No vaccine-related serious adverse events were observed through 12 months after the second vaccine dose. In all DPIV groups, geometric mean antibody titers peaked at Day 56, waned through 6 months after the second vaccine dose, and then stabilized. In the nine subjects where boosting was evaluated, a strong anamnestic response was observed. These results support continuation of the clinical development of this dengue vaccine candidate (clinicaltrials.gov: NCT01666652).

Conflict of interest statement

Disclosure: Alix Collard, Edith Lepine, Jean-François Toussaint, Alexander C. Schmidt, and Bruce Innis are employed by the GSK group of companies. Edith Lepine, Alexander C. Schmidt, Bruce Innis, and Jean-François Toussaint also declare owing stocks, stock options, and/or restricted shares. Leyi Lin, Luis J. Martinez, Rafael De La Barrera, Richard G. Jarman, Kristopher Paolino, and Richard C. Ruck have nothing to disclose. Kenneth H. Eckels has an issued and licensed patent DENV PIV Vaccine with royalties paid to GSK. Stephen J. Thomas declares having received travel support as part of the cooperative agreement between the GSK group of companies and U.S. Army, which was put in place to codevelop the dengue vaccine candidate being reported. These statements are made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.

Figures

Figure 1.
Figure 1.
Disposition of study participants and reasons for exclusion from according-to-protocol cohort for immunogenicity. 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. N = number of participants; ATP = according-to-protocol; Ab = antibody. D56 = Day 56, (1 month post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2). Dashed arrows were used between the different ATP cohorts for immunogenicity to show chronological order (D56, M7, M13), but a cohort is not embedded in the preceding one.
Figure 2.
Figure 2.
Overall per dose incidence of any grade solicited injection site (A) and general (B) adverse events during the 7-day postvaccination period (total vaccinated cohort). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. Error bars indicate exact 95% confidence intervals; GI = gastrointestinal; Temperature = oral temperature ≥ 37.5°C. Intensities of each AE were scored as grades 1–3, with grade 3 fever defined as an oral body temperature ≥ 39°C, grade 3 redness and swelling defined as ≥ 101-mm diameter around the injection site, and all other grade 3 AEs defined as those events preventing normal daily activity.
Figure 3.
Figure 3.
Geometric mean titers to dengue virus types 1–4 up to 1 year post-dose 2 (according-to-protocol cohort for immunogenicity M13). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. Participants with a titer below the assay cutoff of 10 were attributed a titer of 5; DENV = dengue virus type; PRE = prevaccination; D56 = Day 56 (1 month post-dose 2); M4 = Month 4 (3 months post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2). Error bars indicate 95% confidence intervals.
Figure 4.
Figure 4.
Reverse cumulative distribution curves for antibody titers to dengue virus types 1–4 at D56 (according-to-protocol cohort for immunogenicity D56). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. Dotted line indicates cutoff for MN50 = 10 ED50; participants with a titer below the assay cutoff were attributed the arbitrary value of half the cutoff. MN50 = 50% microneutralization assay; DENV = dengue virus type.
Figure 5.
Figure 5.
Seroconversion rates to dengue virus types 1–4 up to 1 year post-dose 2 (according-to-protocol cohort for immunogenicity M13). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. Monovalent, bivalent, trivalent, and tetravalent seropositivity rates are defined as the percentage of subjects who are seropositive to 1, 2, 3, and all 4 DENV types, respectively. No seroconversion was observed in the placebo group, which was therefore not shown. Not all numbers add up to 100% due to rounding. D56 = Day 56 (1 month post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2).
Figure 6.
Figure 6.
Box and whisker plot of avidity index for dengue virus types 1–4 up to 1 year post-dose 2 (adapted according-to-protocol cohort for immunogenicity). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. DENV = dengue virus type; PRE = prevaccination; D28 = Day 28 (1 month post-dose 1); D56 = Day 56 (1 month post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2). According to the time point, the following cohorts were used to create the adapted according-to-protocol cohort for immunogenicity: for PRE, D28, D56: ATP cohort for immunogenicity D56; for M7: ATP cohort for immunogenicity M7 and for M13: ATP cohort for immunogenicity M13. Antibody avidity indices describe polyclonal antibody binding in the absence or presence of 8 M urea, as described in the Materials and Methods section. Boxes and/or whiskers with limits equal to 0 are flattened to a horizontal bar.
Figure 7.
Figure 7.
Avidity index vs. the N antibody titers by MN50 for dengue virus serotypes 1–4 at D56 (adapted according-to-protocol cohort for immunogenicity). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B. DENV = dengue virus serotype; D56 = Day 56 (1 month post-dose 2); Loess = nonparametric local regression fit. According to the time point, the following cohorts were used to create the adapted according-to-protocol cohort for immunogenicity D56: for PRE, D28, D56: ATP cohort for immunogenicity; for M7: ATP cohort for immunogenicity M7 and for M13: ATP cohort for immunogenicity M13.
Figure 8.
Figure 8.
Neutralizing antibody titers to dengue virus serotypes 1–4 up to 28 days postbooster (booster according-to-protocol cohort for immunogenicity). 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E. Participants with a titer below the assay cutoff were attributed the arbitrary value of half the cutoff; DENV = dengue virus serotype; PRE = prevaccination; D56 = Day 56 (1 month post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2); Pre-B = prebooster vaccination, Post-B = 28 days postbooster vaccination.

References

    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013;496:504–507.
    1. World Health Organization . Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. new edition. Geneva, Switzerland: World Health Organization; 2009.
    1. Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011;29:239–247.
    1. Yauch LE, Shresta S. Dengue virus vaccine development. Adv Virus Res. 2014;88:315–372.
    1. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745–759.
    1. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–1567.
    1. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–1365.
    1. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–123.
    1. Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32:1326–1337.
    1. Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg. 2015;92:698–708.
    1. Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ. Safety and immunogenicity of a dengue virus serotype-1 purified inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg. 2015;93:454–460.
    1. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology. 2010;396:280–288.
    1. Fernandez S, Cisney ED, Tikhonov AP, Schweitzer B, Putnak RJ, Simmons M, Ulrich RG. Antibody recognition of the dengue virus proteome and implications for development of vaccines. Clin Vaccine Immunol. 2011;18:523–532.
    1. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Medical Dictionary for Regulatory Activities (MedDRA) 2012. Version 15.0. Available at. Accessed June, 2015.
    1. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013;88:73–88.
    1. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP., Jr Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 2008;78:426–433.
    1. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28:1740–1745.
    1. Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013;31:2196–2206.
    1. George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blind phase I clinical trial. J Infect Dis. 2015;212:1032–1041.
    1. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother. 2014;10:2853–2863.
    1. Dorigatti I, Aguas R, Donnelly CA, Guy B, Coudeville L, Jackson N, Saville M, Ferguson NM. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and south east Asia. Vaccine. 2015;33:3746–3751.
    1. Diaz C, Martinez LJ, Eckels KH, Lin L, Campos M, Jarman RG, Barrera RDL, Lepine E, Collard A, Innis BL, Febo I, Thomas SJ, Schmidt AC. Phase 1 Study of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine (DPIV): Safety and Immunogenicity Data in Healthy Adults from Puerto Rico through Month 13; 64th ASTMH Annual Meeting; October 25–29, 2015; Philadelphia, PA. 2015.
    1. Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine. 2011;29:2607–2612.
    1. Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur adults. Vaccine. 2009;27:853–856.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する